Vorasidenib Improves PFS in Grade 2 Gliomas With Manageable Safety Profile
Neither of the 2 current standards of care offers patients a cure.
Source: pharmacytimes.com
Ingok Mellinghoff News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Ingok Mellinghoff. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Ingok Mellinghoff Today - Breaking & Trending Today
ASCO: Vorasidenib Improves Progression-Free Survival in Grade 2 IDH-Mutant Glioma
Vorasidenib significantly improves progression-free survival among patients with grade 2 isocitrate dehydrogenase (IDH)-mutant glioma.
Source: oncologynurseadvisor.com
Vorasidenib Significantly Improves PFS in Grade 2 Gliomas With Manageable Safety Profile
Current standard of care gives 2 poor options to patients, neither of which cure grade 2 gliomas.
Source: pharmacytimes.com
Servier Presents Transformational Data from Pivotal Phase 3 INDIGO Trial of Vorasidenib in Recurrent or Residual Grade 2 IDH-Mutant Diffuse Glioma
Vorasidenib demonstrated an unprecedented improvement in progression free survival with a median of 27.7 months in patients with residual or recurrent grade 2...
Source: prnewswire.com
Vorasidenib first 'game changer' in 20 years for patients with IDH -mutant grade 2 glioma
CHICAGO — Vorasidenib significantly improved PFS while delaying time to next intervention among certain patients with grade 2 isocitrate dehydrogenase 1- or 2-mutant glioma, according to data presented at ASCO Annual Meeting.The findings, published simultaneously in The New England Journal of Medicine, showed efficacy across all patient subgroups.
Source: healio.com